secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-068534
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Therapeutics reports Q1 net loss $32.7M, cash $106.9M; LX2006 data positive
--------------------------------------------------------------------------------

- Net loss of $32.7M ($0.99 per share) vs $21.7M ($0.77) in Q1 2024; R&D expense $17.2M, G&A $16.6M.
- Cash, cash equivalents and investments of $106.9M expected to fund operations into 2027.
- LX2006 in FA cardiomyopathy: interim data show 25% mean LVMI reduction and 115% avg frataxin increase; registrational study planned by early 2026.
- LX2020 (PKP2-ACM): Cohort 1 showed 71% and 115% PKP2 increases; enrolling cohort 3; interim update expected H2 2025.
- Redeployed $20M from non-cardiac pipeline; limited reduction in force of ~15% employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/0000950170-25-068534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/lxeo-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-068534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer